To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Regional variation i användningen av TTF vid glioblastombehandling: [Regional variation in usage of TTF (Optune)]
Institutionen för kliniska vetenskaper, Lunds universitet; VE onko-logi, Skånes universitetssjukhus.
Institutionen för strålningsvetenskaper, Umeå universitet.
Örebro University, School of Medical Sciences. VO onkologi, Universitetssjukhuset Örebro.ORCID iD: 0000-0001-9858-6684
Institutionen för vårdvetenskap och hälsa, Göteborgs universitet; Region Stockholm-Gotland.
Show others and affiliations
2023 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 120, no 120, article id 22158Article in journal (Refereed) Published
Abstract [en]

The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant trend to better survival was seen for the group of TTF-treated patients compared to individually matched controls. In summary, TTF is a new treatment for glioblastoma, with potential to prolong survival also in real world patients. Today, the treatment is not offered equally to all patients, despite national guidelines.

Abstract [sv]

TTF (tumour treating fields) är en ny, nationellt godkänd utrustning, som inducerar alternerande elektriska fält och används vid behandling av hjärntumören glioblastom.

Behandlingen kan vara inskränkande i vardagen, och data från det nationella registret för CNS-tumörer visar att mer än hälften av patienterna avbryter TTF på grund av dålig användningsgrad eller egen önskan.

Genomsnittlig behandlingstid enligt registret är 164 dagar.

Jämfört med matchade kontroller visar data från registret en trend med längre överlevnad för patienter som behandlas med TTF; dock är skillnaden inte statistiskt signifikant.

Det finns en stor regional variation i andelen patienter som erbjudits behandlingen.

Place, publisher, year, edition, pages
Läkartidningen Förlag AB , 2023. Vol. 120, no 120, article id 22158
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-106939PubMedID: 37401252OAI: oai:DiVA.org:oru-106939DiVA, id: diva2:1779916
Available from: 2023-07-05 Created: 2023-07-05 Last updated: 2023-07-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

PubMedPublisher's fulltext

Authority records

Löfgren, David

Search in DiVA

By author/editor
Löfgren, David
By organisation
School of Medical Sciences
In the same journal
Läkartidningen
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 44 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf